14/09/2018 13:53:26

Scythian Biosciences Announces Execution of Share Purchase Agreement with MMJ International Investments Inc., owner of Argentina-based ABP S.A.

Execution of the Share Purchase Agreement is a Key Benchmark in Finalizing Previously Announced $193 Million Sale of Assets in Caribbean and Latin America

Shares to be Received in Consideration for the Proposed Sale of Assets in Caribbean and Latin America are now Worth Approximately $271 Million As Of Yesterday’s Close of Market

TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl: SCCYF) announces that it has entered into a definitive share purchase agreement (the “Purchase Agreement”) with MMJ International Investments Inc. (“MMJ”), a privately-held British Columbia company and all of the shareholders of MMJ, to acquire all of the issued and outstanding common shares of MMJ (the “Acquisition”).  MMJ is the owner of Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina. ABP also holds a license to import cannabidiol oil into Argentina. The Purchase Agreement supersedes the previously-announced business combination agreement between Scythian and MMJ to effect the Acquisition. Closing of the Acquisition remains subject to a number of conditions including the receipt of all applicable regulatory approvals and third party consents and the completion of the Company’s due diligence investigations of MMJ and ABP.

In accordance with the terms and conditions of the Purchase Agreement, Scythian will satisfy the purchase price by the issuance of 6,176,320 common shares in the capital of the Company (“Common Shares”) to the shareholders of MMJ at a price per share equal to the closing trading price of the Common Shares immediately prior to the closing date. The Company expects the closing to take place on September 17, 2018.

The Acquisition is one of Scythian’s final transactions in South America and the Caribbean, where the Company’s strategic investments and regional partnerships had previously been focused.

The acquisition of MMJ and ABP will continue Scythian’s strategic exit from its South American and Caribbean investments and partnerships, a process which includes the Company’s previously announced disposition of regional assets for an aggregate of $193 million. As disclosed on August 23, 2018, Scythian intends to develop its presence in a number of U.S. states.

Scythian also intends to change its name to SOL Investments Corp. subject to receiving shareholder approval at the Company’s special meeting of shareholders scheduled to take place later today.

About Scythian Biosciences Corp.

Scythian is an international cannabis company with a focus on legal U.S. states. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning Scythian as a future frontrunner in the United States’ medical cannabis industry.

CONTACT INFORMATION

Scythian Biosciences Corp.

Rob Reid, CEO

Phone: (212) 729-9208

Email: info@scythianbio.com

For media inquiries, please contact:

David Schull or Nic Johnson

Russo Partners

(858) 717-2310

david.schull@russopartnersllc.com 

nic.johnson@russopartnersllc.com

Cautionary Statements

This press release contains certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation, statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Such forward-looking information includes information relating to the Acquisition, the Company’s strategic plans and change of name.

Readers are cautioned to not place undue reliance on forward-looking information. Forward-looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Such risks and uncertainties include, among other things, the risk that a condition to the completion of the Acquisition may not be satisfied or that a regulatory approval that may be required for the Acquisition is not obtained or is obtained subject to conditions that are not anticipated.

Other risks and uncertainties include but are not limited to: the Company’s ability to comply with all applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; limited operating history; competition; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use and adult-use marijuana industry and; regulatory or political change. Risk factors can also be found in the Company’s annual information form filed on SEDAR and available at www.sedar.com.

The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Scythian logo.jpg

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Nov
DANSKE
Jeg vil gerne opfordrer jer til at kikke på 6212 indlæg omkring Danske Bank - min oplevelse er at ha..
52
13 Nov
 
Hvis jeg må være så fri at komme med en opfordring til de ansvarlige for dette forum. I skulle prøve..
31
11 Nov
 
Hej,   Jeg lægger kvartals regnskabs-tal ind for samtlige Nordiske selskaber fra Nasdaq OMX og Oslo ..
20
11 Nov
NOVO-B
Novo, Lilly, Sanofi og alle de andre diabetes-butikker er kommet med regnskab. AstraZeneca var den s..
20
14 Nov
CHEMM
Jeg har det lidt som vagabonderne Vladimir og Estragon i Samuel Becketts skuespil,hvor de 2 sidder u..
19
12 Nov
I:NDX
Du virker ret let påvirkelig i dine holdninger, senest:   24/10-18:Sælg nu for pokker. Bear market. ..
19
11 Nov
DANSKE
Det er muligt du syntes det - 6212 er langt langt over stregen......👎
19
11 Nov
DANSKE
Giver dig helt ret 6212 er meget trættende at læse Og jeg forstår ikke hans indlæg ikke bliver slet..
17
15 Nov
VELO
Lidt tanker omkring Velos prissætning og hvorfor jeg stadig finder den absurd undervurderet: De h..
16
10 Nov
NOVO-B
Han er den mest kompetente herinde. Så er lidt ærgerligt at du må den måde sænker / ødelægger forrum..
16

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FSIS Recall Release 112-2018 Salmonella
2
Gulf Island Completes Sale of Texas North Yard
3
FinTech Acquisition Corp. III Announces Pricing of Upsized $300,000,000 Initial Public Offering
4
SUEZ FILES INTENT TO ACQUIRE EAGLE WATER IN IDAHO
5
Laureate Education Announces Pricing of Public Offering by Selling Stockholder

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 November 2018 22:51:27
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181114.1 - EUROWEB6 - 2018-11-16 23:51:27 - 2018-11-16 22:51:27 - 1000 - Website: OKAY